Stock ONCT ONCTERNAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Oncternal Therapeutics, Inc.

Equities

ONCT

US68236P2065

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-30 pm EDT 		5-day change 1st Jan Change
8.31 USD -2.00% Intraday chart for Oncternal Therapeutics, Inc. -5.19% -22.51%
Apr. 18 Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer CI
Apr. 15 HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating MT

Evolution of the average Target Price on Oncternal Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

ebaea22.JhRqb4ANzuCM1rfS18UAdpQHIZMM5Ppqm5ouDCgLxIk.HnMMLfhsvdTtooXmp_1OIOx0cNFLqL483cNmPVBc8tNIRxgI7Fihr86m7g~8a52de211de427dba789c726d07f687c

Analyst Recommendations on Oncternal Therapeutics, Inc.

HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating MT
Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2 MT
HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2 MT
Maxim Downgrades Oncternal Therapeutics to Hold From Buy MT
Oppenheimer Downgrades Oncternal Therapeutics to Perform From Outperform, Removes $9 Price Target MT
Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy MT
Cantor Fitzgerald Adjusts Price Target on Oncternal Therapeutics to $1.30 From $4, Keeps Overweight Rating MT
HC Wainwright Downgrades Oncternal Therapeutics to Neutral From Buy MT
Oppenheimer Adjusts Oncternal Therapeutics Price Target to $9 From $14, Maintains Outperform Rating MT
Cantor Fitzgerald Initiates Oncternal Therapeutics With Overweight Rating, $4 Price Target MT
Maxim Initiates Oncternal Therapeutics at Buy, Sets Price Target at $3.50 MT
BTIG Starts Oncternal Therapeutics at Buy With $5 Price Target MT
ONCTERNAL THERAPEUTICS : Oppenheimer Adjusts Oncternal Therapeutics PT to $16 From $14, Maintains Outperform Rating MT
ONCTERNAL THERAPEUTICS : Oppenheimer Starts Oncternal Therapeutics at Outperform with $14 Price Target MT
ONCTERNAL THERAPEUTICS : Brookline Capital Initiates Coverage on Oncternal Therapeutics With Buy Rating, $16 Price Target MT
ONCTERNAL THERAPEUTICS : Northland Starts Oncternal Therapeutics at Outperform With $21 Price Target MT
Oncternal Therapeutics, Inc. Announces Interim Clinical Data Update, Including 50% Complete Response Rate, for Cirmtuzumab in Combination with Ibrutinib in Patients with Mantle Cell Lymphoma CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.31 USD
Average target price
30.67 USD
Spread / Average Target
+269.02%
High Price Target
39 USD
Spread / Highest target
+369.30%
Low Price Target
25 USD
Spread / Lowest Target
+200.84%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Oncternal Therapeutics, Inc.

HC Wainwright
Brookline Capital Markets
Maxim
Oppenheimer
Cantor Fitzgerald
BTIG
Brookline Capital Management

Ratings for Oncternal Therapeutics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ONCT Stock
  4. Consensus Oncternal Therapeutics, Inc.